CLAIMS

1. A compound comprising the structure of Formula (I):



(I)

wherein:

i) m is 0, 1, 2, or 3;

ii) n is 0, 1, 2, or 3;

iii) o is 0, 1, 2, or 3;

iv) p is 0 or 1;

v) r is 0 or 1;

vi) q is an integer from 1 to 400;

vii) Q^x is NH, $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_9)$heterocycloalkyl, $(C_6\text{-}C_{14})$aryl, $(C_2\text{-}C_9)$heteroaryl;

viii) Q^y is NH-R^w, NH-CH_2-R_w, $(C_1\text{-}C_{10})$alkyl, or $(C_6\text{-}C_{14})$aryl, wherein R^w is absent or a $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_6\text{-}C_{14})$aryl, or $(C_2\text{-}C_9)$heteroaryl;

ix) R^x and R^y are each independently a pharmaceutically acceptable end group.

2. A compound comprising the structure of Formula (II):



(II)

wherein:

i) m is 0, 1, 2, or 3;

ii) n is 0, 1, 2, or 3;

iii) o is 0, 1, 2, or 3;

iv) p is 0 or 1;

v) r is 0 or 1;

vi) q is an integer from 1 to 400;

vii) Q^x is NH, $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_9)$heterocycloalkyl, $(C_6\text{-}C_{14})$aryl, $(C_2\text{-}C_9)$heteroaryl;

viii) Q^y is NH-R^w, NH-CH_2-R_w, $(C_1\text{-}C_{10})$alkyl, or $(C_6\text{-}C_{14})$aryl, wherein R^w is absent or a $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_6\text{-}C_{14})$aryl, or $(C_2\text{-}C_9)$heteroaryl;

ix) R^x and R^y are each independently a pharmaceutically acceptable end group;

x) X is each independently a halo or any pharmaceutically acceptable anion;

xi) Y^1 and Y_2 are each independently H or $(C_1\text{-}C_{10})$alkyl optionally substituted by one or more substituents selected from the group consisting of $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_9)$heterocycloalkyl, $(C_6\text{-}C_{14})$aryl, $(C_2\text{-}C_9)$heteroaryl, $(C_1\text{-}C_{10})$alkylamine, -S-O-$(C_1\text{-}C_{10})$alkyl, -O(O)C-$(C_1\text{-}C_{10})$alkyl, -$(C_1\text{-}C_{10})$alkyl-COOH, $(C_3\text{-}C_{10})$cycloalkyl-COOH, -(O)CH_3, -OH, amide, a dihydroxy group, represented by Formula (D),



(D),

wherein d is an integer from 0 to 25, or

a polyethylene glycol group, represented by Formula (E)



(E)

wherein e is an integer from 1 to 25.

3. A compound comprising the structure of Formula (III):



(III)

wherein:

i) m is 0, 1, 2, or 3;

ii) n is 0, 1, 2, or 3;

iii) o is 0, 1, 2, or 3;

iv) p is 0 or 1;

v) r is 0 or 1;

vi) q is an integer from 1 to 400;

vii) Q^x is NH, $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_9)$heterocycloalkyl, $(C_6\text{-}C_{14})$aryl, $(C_2\text{-}C_9)$heteroaryl;

viii) Q^y is NH-R^w, NH-CH_2-R_w, $(C_1\text{-}C_{10})$alkyl, or $(C_6\text{-}C_{14})$aryl, wherein R^w is absent or a $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_6\text{-}C_{14})$aryl, or $(C_2\text{-}C_9)$heteroaryl;

iii) R^x and R^y are each independently a pharmaceutically acceptable end group;

ix) X^- is a halo or any pharmaceutically acceptable anion;

x) Y^1 is H or $(C_1\text{-}C_{10})$alkyl optionally substituted by one or more substituents selected from the group consisting of $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_9)$heterocycloalkyl, $(C_6\text{-}C_{14})$aryl, $(C_2\text{-}C_9)$heteroaryl, $(C_1\text{-}C_{10})$alkylamine, -S-O-$(C_1\text{-}C_{10})$alkyl, -O(O)C-$(C_1\text{-}C_{10})$alkyl, -$(C_1\text{-}C_{10})$alkyl-COOH, $(C_3\text{-}C_{10})$cycloalkyl-COOH, -$(O)CH_3$, -OH, amide, a dihydroxy group, represented by Formula (D),



(D),

wherein d is an integer from 0 to 25, or

a polyethylene glycol group, represented by Formula (E),



(E)

wherein e is an integer from 1 to 400.

4. The compound according to claim 1 wherein n is 0.
5. The compound according to claim 2 wherein n is 0.
6. The compound according to claim 3 wherein n is 0.
7. The compound according to claim 1 wherein n is 1.
8. The compound according to claim 2 wherein n is 1.
9. The compound according to claim 3 wherein n is 1.
10. The compound according to claim 1 wherein n is 2.
11. The compound according to claim 2 wherein n is 2.
12. The compound according to claim 3 wherein n is 2.
13. The compound according to claim 1 wherein n is 3.
14. The compound according to claim 2 wherein n is 3.
15. The compound according to claim 3 wherein n is 3.
16. The compound according to claim 1 wherein p is 0.
17. The compound according to claim 2 wherein p is 0.
18. The compound according to claim 3 wherein p is 0.
19. The compound according to claim 1 wherein p is 1.
20. The compound according to claim 2 wherein p is 1.
21. The compound according to claim 3 wherein p is 1.
22. The compound according to claim 1 wherein r is 0.
23. The compound according to claim 2 wherein r is 0.
24. The compound according to claim 3 wherein r is 0.
25. The compound according to claim 1 wherein r is 1.
26. The compound according to claim 2 wherein r is 1.
27. The compound according to claim 3 wherein r is 1.
28. The compound according to clam 1 wherein p is 0 and r is 0.
29. The compound according to clam 2 wherein p is 0 and r is 0.
30. The compound according to clam 2 wherein p is 0 and r is 0.
31. The compound according to clam 1 wherein p is 1 and r is 1.
32. The compound according to clam 2 wherein p is 1 and r is 1.

33. The compound according to clam 3 wherein p is 1 and r is 1.

34. The compound according to claim 1 wherein n is 3; p is 1; and r is 1.

35. The compound according to claim 2 wherein n is 3; p is 1; and r is 1.

36. The compound according to claim 3 wherein n is 3; p is 1; and r is 1.

37. The compound according to claim 1 wherein n is 0; p is 1; and r is 1.

38. The compound according to claim 2 wherein n is 0; p is 1; and r is 1.

39. The compound according to claim 3 wherein n is 0; p is 1; and r is 1.

40. The compound according to claim 1 wherein n is 0; p is 0; and r is 0.

41. The compound according to claim 2 wherein n is 0; p is 0; and r is 0.

42. The compound according to claim 3 wherein n is 0; p is 0; and r is 0.

43. The compound according to claim 31 wherein:

i) Q^x is –NH; and

ii) Q^y is NH-R^w-, wherein R^w is a (C_1-C_{10})alkyl, (C_2-C_9)heteroalkyl, (C_6-C_{14})aryl, or (C_2-C_9)heteroaryl.

44. The compound according to claim 32 wherein:

i) Q^x is –NH; and

ii) Q^y is NH-R^w-, wherein R^w is a (C_1-C_{10})alkyl, (C_2-C_9)heteroalkyl, (C_6-C_{14})aryl, or (C_2-C_9)heteroaryl.

45. The compound according to claim 33 wherein:

i) Q^x is –NH; and

ii) Q^y is NH-R^w-, wherein R^w is a (C_1-C_{10})alkyl, (C_2-C_9)heteroalkyl, (C_6-C_{14})aryl, or (C_2-C_9)heteroaryl.

46. The compound according to claim 34 wherein:

i) m is 2;

ii) o is 2;

iii) Q^x is NH; and

iv) Q^y is NH-R^w-, wherein R^w is a (C_3)alkyl.

47. The compound according to claim 35 wherein:

i) m is 2;

ii) o is 2;

iii) Y^1 is H; and

iv) Y^2 is a dihydroxy group, represented by Formula (D),



(D),

wherein d is 1.

48. The compound according to claim 36 wherein:
    i) m is 2;
    ii) o is 2;
    iii) Q^x is NH; and
    iv) Q^y is NH-R^w wherein R^w is a (C_3)alkyl.

49. The compound according to claim 47, wherein the compound is a polymer.

50. The compound according to claim 48, wherein the compound is a polymer.

51. The compound according to claim 49, wherein the polymer is a copolymer with the compound according to claim 50.

52. The compound according to claim 31 wherein:
    i) m is 0; and
    ii) o is 0.

53. The compound according to claim 32 wherein:
    i) m is 0; and
    ii) o is 0.

54. The compound according to claim 33 wherein:
    i) m is 0; and
    ii) o is 0.

55. The compound according to claim 40 wherein:
    i) Q^x is NH; and
    ii) Q^y is N-R^w, wherein R^w is absent or a $(C_1$-$C_{10})$alkyl, $(C_2$-$C_9)$heteroalkyl, $(C_6$-$C_{14})$aryl, or $(C_2$-$C_9)$heteroaryl.

56. The compound according to claim 41 wherein:
    i) Q^x is NH; and
    ii) Q^y is N-R^w, wherein R^w is absent or a $(C_1$-$C_{10})$alkyl, $(C_2$-$C_9)$heteroalkyl, $(C_6$-$C_{14})$aryl, or $(C_2$-$C_9)$heteroaryl.

57. The compound according to claim 42 wherein:
    i) Q^x is NH; and

ii) Q^y is N-R^w, wherein R^w is absent or a (C_1-C_{10})alkyl, (C_2-C_9)heteroalkyl, (C_6-C_{14})aryl, or (C_2-C_9)heteroaryl.

58. The compound according to claim 34 wherein:

i) m is 2;

ii) o is 2;

iii) Q^x is NH;

iv) Q^y is NH-R_w-, wherein R_w is a (C_3)alkyl

v) R^x is a guanidinium chloride group represented by Formula (B),



(B)

wherein b is 3; and

vi) R^y is a guanidinium chloride group represented by Formula (B),



(B)

wherein b is 0.

59. The compound according to claim 35 wherein:

i) m is 2;

ii) o is 2;

iii) Q^x is NH;

iv) Q^y is NH-R_w-, wherein R_w is a (C_3)alkyl

v) R^x is a guanidinium chloride group represented by Formula (B),



(B)

wherein b is 3; and

vi) R^y is a guanidinium chloride group represented by Formula (B),



(B)

wherein b is 0.

60. The compound according to claim 36 wherein:

i) m is 2;

ii) o is 2;

iii) Q^x is NH;

iv) Q^y is NH-R_w-, wherein R_w is a (C_3)alkyl

v) R^x is a guanidinium chloride group represented by Formula (B),



(B)

wherein b is 3; and

vi) R^y is a guanidinium chloride group represented by Formula (B),



(B)

wherein b is 0.

61. A compound comprising the structure of Formula (IV):



(IV)

wherein:

i) u is 0, 1, 2, or 3;

ii) v is 0, 1, 2, or 3;

iii) q is an integer from 1 to 400;

iv) Q^x is NH, $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_9)$heterocycloalkyl, $(C_6\text{-}C_{14})$aryl, $(C_2\text{-}C_9)$heteroaryl;

v) Q^y is NH-R^w, NH-CH_2-R_w, $(C_1\text{-}C_{10})$alkyl, or $(C_6\text{-}C_{14})$aryl, wherein R^w is absent or a $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_6\text{-}C_{14})$aryl, or $(C_2\text{-}C_9)$heteroaryl;

vi) R^x and R^y are each independently a pharmaceutically acceptable end group.

62. A compound comprising the structure of Formula (V):



(V)

wherein:

i) u is 0, 1, 2, or 3;

ii) v is 0, 1, 2, or 3;

iii) q is an integer from 1 to 400;

iv) Q^x is NH, $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_9)$heterocycloalkyl, $(C_6\text{-}C_{14})$aryl, $(C_2\text{-}C_9)$heteroaryl;

v) Q^y is NH-R^w, NH-CH_2-R_w, $(C_1\text{-}C_{10})$alkyl, or $(C_6\text{-}C_{14})$aryl, wherein R^w is absent or a $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_6\text{-}C_{14})$aryl, or $(C_2\text{-}C_9)$heteroaryl;

vi) R^x and R^y are each independently a pharmaceutically acceptable end group;

vii) X^- is independently a halo or any pharmaceutically acceptable anion,

viii) Y^1 and Y^2 are independently H or $(C_1\text{-}C_{10})$alkyl optionally substituted by one or more substituents selected from the group consisting of $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_9)$heterocycloalkyl, $(C_6\text{-}C_{14})$aryl, $(C_2\text{-}C_9)$heteroaryl, $(C_1\text{-}C_{10})$alkylamine, -S-O-$(C_1\text{-}C_{10})$alkyl, -O(O)C-$(C_1\text{-}C_{10})$alkyl, -$(C_1\text{-}C_{10})$alkyl-COOH, $(C_3\text{-}C_{10})$cycloalkyl-COOH, -(O)CH_3, -OH, amide, a dihydroxy group, represented by Formula (D),



(D),

wherein d is an integer from 0 to 25, or

a polyethylene glycol group, represented by Formula (E)



(E)

wherein e is an integer from 1 to 400.

63. The compound according to claim 61 wherein u is 0.
64. The compound according to claim 62 wherein u is 0.
65. The compound according to claim 61 wherein u is 1.
66. The compound according to claim 62 wherein u is 1.
67. The compound according to claim 61 wherein u is 2.
68. The compound according to claim 62 wherein u is 2.
69. The compound according to claim 61 wherein u is 3.
70. The compound according to claim 62 wherein u is 3.
71. The compound according to claim 61 wherein v is 0.
72. The compound according to claim 62 wherein v is 0.
73. The compound according to claim 61 wherein v is 1.
74. The compound according to claim 62 wherein v is 1.
75. The compound according to claim 61 wherein v is 2.
76. The compound according to claim 62 wherein v is 2.
77. The compound according to claim 61 wherein v is 3.
78. The compound according to claim 62 wherein v is 3.
79. The compound according to claim 61 wherein u is 2 and v is 2.
80. The compound according to claim 62 wherein u is 2 and v is 2.
81. The compound according to claim 79 wherein:

i) Q_x is NH;

ii) Q_y is NH-CH_2-R_w,

wherein R_w is a (C_1-C_{10})alkyl, (C_2-C_9)heteroalkyl, (C_6-C_{14})aryl, or (C_2-C_9)heteroaryl.

82. The compound according to claim 80 wherein:

i) Q_x is NH;

ii) Q_y is NH-CH_2-R_w,

wherein R_w is a (C_1-C_{10})alkyl, (C_2-C_9)heteroalkyl, (C_6-C_{14})aryl, or (C_2-C_9)heteroaryl.

83. The compound according to claim 1, wherein R^x and R^y are each independently H, (C_1-C_{10})alkyl, (C_2-C_0)heteroalkyl, (C_3-C_{10})cycloalkyl, (C_2-C_9)heterocycloalkyl, (C_6-C_{14})aryl, (C_2-C_9)heteroaryl, (C_1-C_{10})alkylamine, -O(O)C-(C_1-C_{10})alkyl, (C_1-C_{10})alkyl-COOH, (C_3-C_{10})cycloalkyl-COOH, -(O)CH_3, -OH, amide, a guanidino group represented by Formula (A)



(A)

wherein a is an integer from 0 to 25,

a guanidinium chloride group represented by Formula (B),



(B)

wherein b is an integer from 0 to 25,

a guanidinobenzene group represented by Formula (C),



(C)

wherein c is an integer from 0 to 25,

a dihydroxy group, represented by Formula (D),



(D),

wherein d is an integer from 0 to 25, or

a polyethylene glycol group, represented by Formula (E)



(E)

wherein e is an integer from 1 to 400.

84. The compound according to claim 83, wherein R^x and R^y are each independently selected from -(O)CH_3, a guanidino group represented by Formula (A)



(A)

wherein a is an integer from 0 to 25, or

a guanidinobenzene group represented by Formula (C),



(C)

wherein c is an integer from 0 to 25.

85. The compound according to claim 2, wherein R^x and R^y are each independently H, (C_1-C_{10})alkyl, (C_2-C_0)heteroalkyl, (C_3-C_{10})cycloalkyl, (C_2-C_9)heterocycloalkyl, (C_6-C_{14})aryl, (C_2-C_9)heteroaryl, (C_1-C_{10})alkylamine, -O(O)C-(C_1-C_{10})alkyl, (C_1-C_{10})alkyl-COOH, (C_3-C_{10})cycloalkyl-COOH, -(O)CH_3, -OH, amide, a guanidino group represented by Formula (A)



(A)

wherein a is an integer from 0 to 25,

a guanidinium chloride group represented by Formula (B),



(B)

wherein b is an integer from 0 to 25,

a guanidinobenzene group represented by Formula (C),



(C)

wherein c is an integer from 0 to 25,

a dihydroxy group, represented by Formula (D),



(D),

wherein d is an integer from 0 to 25, or

a polyethylene glycol group, represented by Formula (E)



(E)

wherein e is an integer from 1 to 400.

86. The compound according to claim 85, wherein R^x and R^y are each independently selected from -(O)CH_3, a guanidino group represented by Formula (A)



(A)

wherein a is an integer from 0 to 25, or

a guanidinobenzene group represented by Formula (C),



(C)

wherein c is an integer from 0 to 25.

87. The compound according to claim 3, wherein R^x and R^y are each independently H, (C_1-C_{10})alkyl, (C_2-C_0)heteroalkyl, (C_3-C_{10})cycloalkyl, (C_2-C_9)heterocycloalkyl, (C_6-C_{14})aryl, (C_2-C_9)heteroaryl, (C_1-C_{10})alkylamine, -O(O)C-(C_1-C_{10})alkyl, (C_1-C_{10})alkyl-COOH, (C_3-C_{10})cycloalkyl-COOH, -(O)CH_3, -OH, amide, a guanidino group represented by Formula (A)



(A)

wherein a is an integer from 0 to 25,

a guanidinium chloride group represented by Formula (B),



(B)

wherein b is an integer from 0 to 25,

a guanidinobenzene group represented by Formula (C),



(C)

wherein c is an integer from 0 to 25,

a dihydroxy group, represented by Formula (D),



(D),

wherein d is an integer from 0 to 25, or

a polyethylene glycol group, represented by Formula (E)



(E)

wherein e is an integer from 1 to 400.

88. The compound according to claim 87, wherein R^x and R^y are each independently selected from -(O)CH_3, a guanidino group represented by Formula (A)



(A)

wherein a is an integer from 0 to 25, or

a guanidinobenzene group represented by Formula (C),



(C)

wherein c is an integer from 0 to 25.

89. The compound according to claim 61, wherein R^x and R^y are each independently H, (C_1-C_{10})alkyl, (C_2-C_0)heteroalkyl, (C_3-C_{10})cycloalkyl, (C_2-C_9)heterocycloalkyl, (C_6-C_{14})aryl, (C_2-C_9)heteroaryl, (C_1-C_{10})alkylamine, -O(O)C-(C_1-C_{10})alkyl, (C_1-C_{10})alkyl-COOH, (C_3-C_{10})cycloalkyl-COOH, -(O)CH_3, -OH, amide, a guanidino group represented by Formula (A),



(A)

wherein a is an integer from 0 to 25,

a guanidinium chloride group represented by Formula (B),



(B)

wherein b is an integer from 0 to 25,

a guanidinobenzene group represented by Formula (C),



(C)

wherein c is an integer from 0 to 25,

a dihydroxy group, represented by Formula (D),



(D),

wherein d is an integer from 0 to 25, or

a polyethylene glycol group, represented by Formula (E)



(E)

wherein e is an integer from 1 to 400.

90. The compound according to claim 89, wherein R^x and R^y are each independently selected from -(O)CH_3, a guanidino group represented by Formula (A)



(A)

wherein a is an integer from 0 to 25, or

a guanidinobenzene group represented by Formula (C),



(C)

wherein c is an integer from 0 to 25.

91. The compound according to claim 62, wherein R^x and R^y are each independently H, (C_1-C_{10})alkyl, (C_2-C_0)heteroalkyl, (C_3-C_{10})cycloalkyl, (C_2-C_9)heterocycloalkyl, (C_6-C_{14})aryl, (C_2-C_9)heteroaryl, (C_1-C_{10})alkylamine, -O(O)C-(C_1-C_{10})alkyl, (C_1-C_{10})alkyl-COOH, (C_3-C_{10})cycloalkyl-COOH, -(O)CH_3, -OH, amide, a guanidino group represented by Formula (A)



(A)

wherein a is an integer from 0 to 25,

a guanidinium chloride group represented by Formula (B),



(B)

wherein b is an integer from 0 to 25,

a guanidinobenzene group represented by Formula (C),



(C)

wherein c is an integer from 0 to 25,

a dihydroxy group, represented by Formula (D),



(D),

wherein d is an integer from 0 to 25, or

a polyethylene glycol group, represented by Formula (E)



(E)

wherein e is an integer from 1 to 400.

92. The compound according to claim 91, wherein R^x and R^y are each independently selected from -(O)CH_3, a guanidino group represented by Formula (A)



(A)

wherein a is an integer from 0 to 25, or

a guanidinobenzene group represented by Formula (C),



(C)

wherein c is an integer from 0 to 25.

93. A pharmaceutical composition comprising a compound according to claim 1.

94. A pharmaceutical composition comprising a compound according to claim 2.

95. A pharmaceutical composition comprising a compound according to claim 3.

96. A pharmaceutical composition comprising a compound according to claim 61.

97. A pharmaceutical composition comprising a compound according to claim 62.

98. The pharmaceutical composition according to claim 93 for use in the treatment of mucositis.

99. The pharmaceutical composition according to claim 94 for use in the treatment of mucositis.

100. The pharmaceutical composition according to claim 95 for use in the treatment of mucositis.

101. The pharmaceutical composition according to claim 96 for use in the treatment of mucositis.

102. The pharmaceutical composition according to claim 97 for use in the treatment of mucositis.

103. The pharmaceutical composition according to claim 93 for use in the treatment of oral mucositis.

104. The pharmaceutical composition according to claim 94 for use in the treatment of oral mucositis.

105. The pharmaceutical composition according to claim 95 for use in the treatment of oral mucositis.

106. The pharmaceutical composition according to claim 96 for use in the treatment of oral mucositis.

107. The pharmaceutical composition according to claim 97 for use in the treatment of oral mucositis.

108. The pharmaceutical composition according to claim 93 for use in the treatment of infection.

109. The pharmaceutical composition according to claim 94 for use in the treatment of infection.
110. The pharmaceutical composition according to claim 95 for use in the treatment of infection.
111. The pharmaceutical composition according to claim 96 for use in the treatment of infection.
112. The pharmaceutical composition according to claim 97 for use in the treatment of infection.
113. The pharmaceutical composition according to claim 108, wherein the infection is a surgical site infection.
114. The pharmaceutical composition according to claim 108, wherein the infection is a lung infection associated with cystic fibrosis.
115. The pharmaceutical composition according to claim 114, wherein the infection is a *Pseudomonas aeruginosa* lung infection.
116. The pharmaceutical composition according to claim 115, wherein biofilms are present in the *Pseudomonas aeruginosa* lung infection.
117. The pharmaceutical composition according to claim 109, wherein the infection is a surgical site infection.
118. The pharmaceutical composition according to claim 109, wherein the infection is a lung infection associated with cystic fibrosis.
119. The pharmaceutical composition according to claim 118, wherein the infection is a *Pseudomonas aeruginosa* lung infection.
120. The pharmaceutical composition according to claim 119, wherein biofilms are present in the *Pseudomonas aeruginosa* lung infection.
121. The pharmaceutical composition according to claim 110, wherein the infection is a surgical site infection.
122. The pharmaceutical composition according to claim 110, wherein the infection is a lung infection associated with cystic fibrosis.
123. The pharmaceutical composition according to claim 122, wherein the infection is a *Pseudomonas aeruginosa* lung infection.
124. The pharmaceutical composition according to claim 123, wherein biofilms are present in the *Pseudomonas aeruginosa* lung infection.

125. The pharmaceutical composition according to claim 111, wherein the infection is a surgical site infection.
126. The pharmaceutical composition according to claim 111, wherein the infection is a lung infection associated with cystic fibrosis.
127. The pharmaceutical composition according to claim 126, wherein the infection is a *Pseudomonas aeruginosa* lung infection.
128. The pharmaceutical composition according to claim 127, wherein biofilms are present in the *Pseudomonas aeruginosa* lung infection.
129. The pharmaceutical composition according to claim 112, wherein the infection is a surgical site infection.
130. The pharmaceutical composition according to claim 112, wherein the infection is a lung infection associated with cystic fibrosis.
131. The pharmaceutical composition according to claim 130, wherein the infection is a *Pseudomonas aeruginosa* lung infection.
132. The pharmaceutical composition according to claim 131, wherein biofilms are present in the *Pseudomonas aeruginosa* lung infection.
133. A method of treating a condition selected from mucositis, oral mucositis, and infection comprising administering a compound according to claim 1.
134. A method of treating a condition selected from mucositis, oral mucositis, and infection comprising administering a compound according to 2.
135. A method of treating a condition selected from mucositis, oral mucositis, and infection comprising administering a compound according to 3
136. A method of treating a condition selected from mucositis, oral mucositis, and infection comprising administering a compound according to 61.
137. A method of treating a condition selected from mucositis, oral mucositis, and infection comprising administering a compound according to 62.
138. The method according to claim 133, wherein the infection is a surgical site infection.
139. The method according to claim 133, wherein the infection is a lung infection associated with cystic fibrosis.
140. The method according to claim 139, wherein the infection is a *Pseudomonas aeruginosa* lung infection.
141. The method according to claim 140, wherein biofilms are present in the *Pseudomonas aeruginosa* lung infection.

142. The method according to claim 134, wherein the infection is a surgical site infection.
143. The method according to claim 134, wherein the infection is a lung infection associated with cystic fibrosis.
144. The method according to claim 143, wherein the infection is a *Pseudomonas aeruginosa* lung infection.
145. The method according to claim 144, wherein biofilms are present in the *Pseudomonas aeruginosa* lung infection.
146. The method according to claim 135, wherein the infection is a surgical site infection.
147. The method according to claim 135, wherein the infection is a lung infection associated with cystic fibrosis.
148. The method according to claim 147, wherein the infection is a *Pseudomonas aeruginosa* lung infection.
149. The method according to claim 148, wherein biofilms are present in the *Pseudomonas aeruginosa* lung infection.
150. The method according to claim 136, wherein the infection is a surgical site infection.
151. The method according to claim 136, wherein the infection is a lung infection associated with cystic fibrosis.
152. The method according to claim 151, wherein the infection is a *Pseudomonas aeruginosa* lung infection.
153. The method according to claim 152, wherein biofilms are present in the *Pseudomonas aeruginosa* lung infection.
154. The method according to claim 137, wherein the infection is a surgical site infection.
155. The method according to claim 137, wherein the infection is a lung infection associated with cystic fibrosis.
156. The method according to claim 155, wherein the infection is a *Pseudomonas aeruginosa* lung infection.
157. The method according to claim 156, wherein biofilms are present in the *Pseudomonas aeruginosa* lung infection.

CLAIMS

1. A compound comprising the structure of Formula (I):



(I)

wherein:

i) m is 1, 2, or 3;

ii) n is 0, 1, 2, or 3;

iii) o is 1, 2, or 3;

iv) p is 0 or 1;

v) r is 0 or 1;

vi) q is an integer from 1 to 400;

vii) Q^x is NH, $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_9)$heterocycloalkyl, $(C_6\text{-}C_{14})$aryl, $(C_2\text{-}C_9)$heteroaryl;

viii) Q^y is NH-R^w, NH-CH_2-R_w, $(C_1\text{-}C_{10})$alkyl, or $(C_6\text{-}C_{14})$aryl, wherein R^w is absent or a $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_9)$heteroalkyl, $(C_6\text{-}C_{14})$aryl, or $(C_2\text{-}C_9)$heteroaryl;

ix) R^x and R^y are each independently a pharmaceutically acceptable end group.

2. The compound according to claim 1 wherein n is 0.

3. The compound according to claim 1 wherein n is 1.

4. The compound according to claim 1 wherein n is 2.

5. The compound according to claim 1 wherein n is 3.

6. The compound according to claim 1 wherein p is 0.

7. The compound according to claim 1 wherein p is 1.

8. The compound according to claim 1 wherein r is 0.

9. The compound according to claim 1 wherein r is 1.

10. The compound according to clam 1 wherein p is 0 and r is 0.

11. The compound according to clam 1 wherein p is 1 and r is 1.

12. The compound according to claim 1 wherein n is 3; p is 1; and r is 1.

13. The compound according to claim 1 wherein n is 0; p is 1; and r is 1.

14. The compound according to claim 1 wherein n is 0; p is 0; and r is 0.

15. The compound according to claim 11 wherein:

    i) Q^x is –NH; and

    ii) Q^y is NH-R^w-, wherein R^w is a (C_1-C_{10})alkyl, (C_2-C_9)heteroalkyl, (C_6-C_{14})aryl, or (C_2-C_9)heteroaryl.

16. The compound according to claim 12 wherein:

    i) m is 2;

    ii) o is 2;

    iii) Q^x is NH; and

    iv) Q^y is NH-R^w-, wherein R^w is a (C_3)alkyl.

17. The compound according to claim 14 wherein:

    i) Q^x is NH; and

    ii) Q^y is N-R^w, wherein R^w is absent or a (C_1-C_{10})alkyl, (C_2-C_9)heteroalkyl, (C_6-C_{14})aryl, or (C_2-C_9)heteroaryl.

18. The compound according to claim 12 wherein:

    i) m is 2;

    ii) o is 2;

    iii) Q^x is NH;

    iv) Q^y is NH-R_w-, wherein R_w is a (C_3)alkyl

    v) R^x is a guanidinium chloride group represented by Formula (B),



(B)

wherein b is 3; and

    vi) R^y is a guanidinium chloride group represented by Formula (B),



(B)

wherein b is 0.

19. The compound according to claim 1, wherein R^x and R^y are each independently H, (C_1-C_{10})alkyl, (C_2-C_0)heteroalkyl, (C_3-C_{10})cycloalkyl, (C_2-C_9)heterocycloalkyl, (C_6-C_{14})aryl, (C_2-C_9)heteroaryl; (C_1-C_{10})alkylamine, -O(O)C-(C_1-C_{10})alkyl, (C_1-C_{10})alkyl-COOH, (C_3-C_{10})cycloalkyl-COOH, -(O)CH_3, -OH, amide, a guanidino group represented by Formula (A)



(A)

wherein a is an integer from 0 to 25,

a guanidinium chloride group represented by Formula (B),



(B)

wherein b is an integer from 0 to 25,

a guanidinobenzene group represented by Formula (C),



(C)

wherein c is an integer from 0 to 25,

a dihydroxy group, represented by Formula (D),



(D)

wherein d is an integer from 0 to 25, or

a polyethylene glycol group, represented by Formula (E)



(E)

wherein e is an integer from 1 to 400.

20. The compound according to claim 19, wherein R^x and R^y are each independently selected from -(O)CH_3, a guanidino group represented by Formula (A)



(A)

wherein a is an integer from 0 to 25, or

a guanidinobenzene group represented by Formula (C),



(C)

wherein c is an integer from 0 to 25.

21. A pharmaceutical composition comprising a compound according to claim 1.

22. The pharmaceutical composition according to claim 21 for use in the treatment of oral mucositis.